Apotex Patent-Cliff Exposure & CMS Drug Spending Portfolio

Apotex (Weston, FL): 20 reconciled FDA prescription therapies (0.3% 2025 to 2030 cliff risk), $289.1M 2024 CMS Part D & Medicaid spend, and 39 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterWeston, FL
Reconciled FDA Portfolio Therapies20
2025 to 2030 Patent-Cliff Revenue Exposure0.3%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$289.1M
2024 Medicare Part D Spend$177.9M
2024 Medicaid Spend$111.2M
California HCAI SB 17 Filings39 WAC filings (max 59.9% 2-yr change)